Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.
Esophageal cancer patients with specific gene mutations respond better to immunotherapy, offering a biomarker beyond current testing methods.
Analyzing a large Caris-sequenced esophageal cancer cohort, this study establishes KMT2 family histone methyltransferase mutations as a clinically meaningful molecular subset of esophageal adenocarcinoma with significantly better immunotherapy outcomes—identifying a potential biomarker for ICI selection in EA distinct from PD-L1 or MSI-H alone. The esophageal squamous cell carcinoma subset does not share this immunotherapy benefit, highlighting histology-specific interpretation.
What the study was
- Study design
- retrospective_genomic_cohort
- Population
- Esophageal carcinoma (adenocarcinoma and squamous cell)
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Oncogene
Why it surfaced
KMT2 mutations are common epigenetic alterations across multiple cancers; EA is a rising incidence malignancy with limited second-line options; immunotherapy OS benefit in KMT2-MT EA could enable a new patient selection strategy; Caris database access provides large-scale real-world genomic validation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.